TNFα-IP 2 Antibody (F-6): sc-28318

TNFα-IP 2 Antibody (F-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects TNFα-IP 2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). TNFα-IP 2 (F-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TNFα-IP 2, also known as B94 or TNFAIP2, is a member of the Sec6 family and plays a crucial role in mediating inflammation and angiogenesis, processes that are vital for tissue repair and regeneration. TNFα-IP 2 is differentially expressed during development and is particularly important in capillary tube-like formation in vitro, highlighting TNFα-IP 2′s significance in vascular biology. TNFAIP2 gene, which maps to chromosome 14q32, encodes a 654 amino acid protein that is induced by tumor necrosis factor alpha and other proinflammatory factors, making TNFα-IP 2 a key player in the inflammatory response. Originally identified as a gene induced in endothelial cells, TNFAIP2 has also been implicated in various cancers, including acute promyelocytic leukemia, where TNFα-IP 2 is upregulated by retinoic acid. With diverse applications and critical biological functions, anti-TNFα-IP 2 antibody (F-6) is an essential tool for researchers studying inflammation, angiogenesis, and related pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TNFα-IP 2 Antibody (F-6) References:

1. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.  |  Rusiniak, ME., et al. 2000. Cancer Res. 60: 1824-9. PMID: 10766166
2. Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman.  |  Einstein, MH., et al. 2002. Clin Cancer Res. 8: 549-54. PMID: 11839676
3. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays.  |  Park, DJ., et al. 2003. Blood. 102: 3727-36. PMID: 12893766
4. Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.  |  Ma, Y., et al. 2003. Oncogene. 22: 4924-32. PMID: 12894236
5. Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro.  |  Sarma, V., et al. 1992. J Immunol. 148: 3302-12. PMID: 1374453
6. Congenic mapping of type 1 diabetes--protective gene(s) in an interval of 4 Mb on rat chromosome 6q32.  |  Klöting, N. and Klöting, I. 2004. Biochem Biophys Res Commun. 323: 388-94. PMID: 15369764
7. The roles of TNFAIP2 in cancers and infectious diseases.  |  Jia, L., et al. 2018. J Cell Mol Med. 22: 5188-5195. PMID: 30145807
8. Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy.  |  Barutta, F., et al. 2023. Autophagy. 19: 505-524. PMID: 35659195
9. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.  |  Xu, T., et al. 2023. J Exp Clin Cancer Res. 42: 190. PMID: 37525222
10. Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1.  |  Fang, H., et al. 2023. Elife. 12: PMID: 37787041
11. TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms.  |  Fu, Z. and Yuan, Y. 2024. Pharmacol Res. 204: 107199. PMID: 38688431
12. B94, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome.  |  Wolf, FW., et al. 1994. J Biol Chem. 269: 3633-40. PMID: 8106408

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TNFα-IP 2 Antibody (F-6) has 21 citations in a variety of scientific publications.

Primary antibodies like Anti-TNFα-IP 2 Antibody (F-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TNFα-IP 2 Antibody (F-6) Specifications

Alternate Product Name: TNFAIP2

Product Clone Name: F-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-654

Epitope Target: TNFα-IP 2

Epitope Species: human

Product Reactivity/Detection: TNFα-IP 2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 21 citations in various scientific publications

Available Conjugates/Forms for TNFα-IP 2 Antibody (F-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin